ORAL ILOPROST ADMINISTERED FOR SEVERE PERIPHERAL ARTERIAL OCCLUSION

口服伊洛前列素治疗严重外周动脉闭塞

• 批准号: 6113633
• 负责人: FRED A WEAVER
• 金额: $ 3.97万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6113633
• 关键词: artery occlusion; cardiovascular disorder chemotherapy; clinical research; clinical trials; dosage; human subject; human therapy evaluation; iloprost; longitudinal human study; oral administration; placebos

This is a prospective double-blind, placebo-controlled, parallel-group, multi-national study of 600 patients with PAOD III and IV who will be randomly assigned to one of the following treatments for 6 months t oral iloprost 50 mcg bid, or oral iloprost 100-150 mcg bid, or matching placebo bid.

这是一项前瞻性双盲、安慰剂对照、平行组研究， 在600例PAOD III和IV患者中开展的一项多国研究， 随机分配至以下治疗之一，持续6个月，口服 伊洛前列素50 mcg bid，或口服伊洛前列素100-150 mcg bid，或匹配安慰剂 bid.